Camille Villequey

This person is no longer with EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation

Christian Heinis, Camille Villequey, Xudong Kong, Kaycie Marie Butler, Vanessa Carle, Christina Lamers, Tamara Maric, Chloé Rogg, Cristina Diaz Perlas

Coagulation factor XI (FXI) has emerged as a promising target for the development of safer anticoagulation drugs that limit the risk of severe and life-threatening bleeding. Herein, we report the first cyclic peptide-based FXI inhibitor that selectively an ...

2021

Cyclization of peptides with two chemical bridges affords large scaffold diversities

Christian Heinis, Alessandro Zorzi, Camille Villequey, Sangram Shivdas Kale, Xudong Kong

2018

New methods for developing (bi)cyclic peptides by phage display

Camille Villequey

Cyclic peptide ligands are a promising molecular format for the development of therapeutics. They combine some of the advantages of large protein therapeutics (high affinity and specificity) and of small molecule drugs (accessibility to chemical synthesis ...

EPFL2017

Bypassing bacterial infection in phage display by sequencing DNA released from phage particles

Christian Heinis, Camille Villequey, Xudong Kong

Phage display relies on a bacterial infection step in which the phage particles are replicated to perform multiple affinity selection rounds and to enable the identification of isolated clones by DNA sequencing. While this process is efficient for wild-typ ...

2017

Page 1 of 1